Hôpital privé du Confluent

InstitutionResearch output, impact & collaborations

Hôpital privé du Confluent is a research organisation in Nantes, FR. OpenAlex records 512 works and 10,435 citations for it. 134 researchers list it as their most recent affiliation.

512

Works

10,435

Citations

134

Researchers

Avg h-index

IDs:ROR OpenAlex

How has Hôpital privé du Confluent's publication output changed over time?

ScholarIQpublication output · 2011–2022

Output grew0% over the shown period — from 1 works in 2011 to 1 in 2022.

201120192022

What are the most-cited papers on Hôpital privé du Confluent?

ScholarIQmost cited works

A Phase 3 Trial of Bevacizumab in Ovarian Cancer

Timothy Perren, Ann Marie Swart, Jacobus Pfisterer, Jonathan A. Ledermann, Éric Pujade-Lauraine, Gunnar B. Kristensen, Mark S. Carey, Philip Beale, Andrés Cervantes, Christian Kurzeder, Andreas du Bois, Jalid Sehouli, Rainer Kimmig, Anne Stähle, Fiona Collinson, Sharadah Essapen, Charlie Gourley, Alain Lortholary, Frédèric Selle, Mansoor R. Mirza, Arto Leminen, Marie Plante, Dan Stark, Wendi Qian, Mahesh Parmar, Amit M. Oza

New England Journal of Medicine. 20112,162 CitationsOPEN ACCESS

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer

Isabelle Ray‐Coquard, Patricia Pautier, Sandro Pignata, David Pérol, Antonio González-Martı́n, Regina Berger, Keiichi Fujiwara, Ignace Vergote, Nicoletta Colombo, Johanna Mäenpää, Frédèric Selle, Jalid Sehouli, Domenica Lorusso, Eva María Guerra Alia, Alexander Reinthaller, Shoji Nagao, Claudia Lefeuvre‐Plesse, Ulrich Canzler, Giovanni Scambia, Alain Lortholary, Frederik Marmé, Pierre Combe, Nikolaus de Gregorio, Manuel Rodrigues, Paul Buderath, Coraline Dubot, Alexander Burges, Benoît You, Éric Pujade-Lauraine, Philipp Harter

New England Journal of Medicine. 20192,070 CitationsOPEN ACCESS

Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial

François‐Clément Bidard, François-Clément Bidard, Anne‐Claire Hardy‐Bessard, Florence Dalenc, Thomas Bachelot, Jean-Yves Pierga, Thibault de la Motte Rouge, Renaud Sabatier, Coraline Dubot, Jean-Sébastien Frenel, Jean Marc Ferrero, Sylvain Ladoire, Christelle Levy, Marie-Ange Mouret-Reynier, Alain Lortholary, Julien Grenier, Camille Chakiba, Laetitia Stefani, Jérôme Edouard Plaza, Florian Clatot, Luis Teixeira, Véronique D'Hondt, Hélène Vegas, Olfa Derbel, Claire Garnier-Tixidré, Jean-Luc Canon, Barbara Pistilli, Fabrice André, Laurent Arnould, Anne Pradines, Ivan Bièche, Céline Callens, Jérôme Lemonnier, Frédérique Berger, Suzette Delaloge, Francois-Clement BIDARD, Francois-Clement BIDARD, Barbara PISTILLI, Florence DALENC, Thomas BACHELOT, Thibault De La Motte Rouge, Renaud SABATIER, Coraline DUBOT, Jean-Sébastien FRENEL, Jean-Marc FERRERO, Sylvain Ladoire, Christelle LEVY, Marie-Ange MOURET-REYNIER, Anne-Claire HARDY-BESSARD, Alain Lortholary, Julien GRENIER, Camille Chakiba, Laetitia STEFANI, P Soulié, Jean-Philippe Jacquin, Jérôme Edouard PLAZA, Florian CLATOT, Luis TEIXEIRA, Véronique D’Hondt, Hélène VEGAS, Olfa DERBEL, Claire Garnier Tixidre, Catherine Delbaldo, Lionel MOREAU, Caroline Cheneau, Jean-François Paitel, Chantal BERNARD-MARTY, Dominique Spaëth, Dominique Genet, Isabelle MOULLET, Nathalie BONICHON-LAMICHHANE, Laura DEIANA, Charlotte GREILSAMER, Laurence Venat‐Bouvet, Valérie Delecroix, Adrien MELIS, Hubert Orfeuvre, Suzanne Nguyen, Éric Legouffe, Alain Zannetti, Romuald Le Scodan, Nadine Dohollou, Philippe DALIVOUST, Olivier Arsène, Nathalie MARQUES, Thierry Petit, Delphine MOLLON, Jérôme Dauba, Nathalie Bonnin, François MORVAN, Miriam Gardner, Adina MARTI, Charles-Briac Levaché, Emma Lachaier, Mihaela ACHILLE, Christophe VALMAR, Ryan Bouaita, Jacques Médioni, Cyril Foa, Chantal BERNARD-MARTY

The Lancet Oncology. 2022331 Citations